A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.
Cardiovascular disease (CVD) is the leading cause of mortality in end-stage renal disease (ESRD) patients and there is emerging evidence that genetic factors may contribute to the development of atherosclerosis. Myeloperoxidase (MPO) is an abundant enzyme involved in the production of free radicals. A functional G-->A single nucleotide polymorphism (SNP) has been identified at position -463, where the A allele is associated with lower MPO expression. To analyze the association between this SNP and inflammation, oxidative stress, and CVD, we studied a cohort of 155 ESRD patients (52 +/- 1 years, 62% males, 22% diabetics) shortly before the initiation of dialysis treatment. CVD was defined by medical history criteria; plasma interleukin-6 (IL-6) was used as a marker of inflammation, and plasma pentosidine as an estimation of oxidative protein damage. DNA from leukocytes was used for genotyping, performed by the pyrosequencing reaction. Only five patients (3%) had the genotype AA at the -463 position, whereas 38 (25%) had the GA and 112 (72%) had the GG genotype. No differences were noted in plasma IL-6 levels between the genotype groups, whereas the pentosidine levels were higher in the GG group (28.4 pmol/mg albumin [range, 8.5 to 123 pmol/mg albumin]) compared to the other two groups (21.4 pmol/mg albumin [range, 7.6 to 384 pmol/mg albumin; P < 0.05]). Patients with the GG genotype had a higher prevalence of positive serology for Chlamydia pneumoniae (51%) when compared to the carriers of the A allele (24%) (P < 0.05). The prevalence of CVD was lower in the AA (0%) and GA genotypes (18%), compared to the GG genotype (35%). The GG genotype was still associated with CVD after correction for age, diabetes, smoking, malnutrition, and inflammation. Our findings suggest that the -463 G-->A SNP, which supposedly results in lower MPO activity, is associated with a lower prevalence of CVD in ESRD patients. It could be speculated that this effect is mediated by a decreased oxidative stress due to lower production of free radicals.
Pecoits-Filho
Roberto
R
Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Karolinska Institutet, Sweden. roberto.pecoits-filho@klinvet.ki.se
Stenvinkel
Peter
P
Marchlewska
Alicia
A
Heimburger
Olof
O
Bárány
Peter
P
Hoff
Catherine M
CM
Holmes
Clifford J
CJ
Suliman
Mohamed
M
Lindholm
Bengt
B
Schalling
Martin
M
Nordfors
Louise
L
D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D001161:Arteriosclerosis / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology; D002690:Chlamydia Infections / Q000453:epidemiology / Q000276:immunology; D016993:Chlamydophila pneumoniae / Q000276:immunology; D003928:Diabetic Nephropathies / Q000453:epidemiology / Q000235:genetics / Q000276:immunology; D005260:Female; D005838:Genotype; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D009195:Peroxidase / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
D001120:Arginine; C062187:pentosidine; D009195:Peroxidase; D008239:Lysine